MPM
ALLO icon

MBB Public Markets’s Allogene Therapeutics ALLO Stock Holding History

MBB Public Markets’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-57,306
Closed -$184K – 289
2023
Q4 		$184K Hold
57,306
– – 0.01% 93
2023
Q3 		$182K Sell
57,306
-28,497
-33% -$125K 0.01% 127
2023
Q2 		$426K Buy
85,803
+32,206
+60% +$174K 0.02% 112
2023
Q1 		$265K Buy
+53,597
New +$344K 0.01% 92

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MBB Public Markets's ALLO Position: Q1 2024 in Review

MBB Public Markets sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 57,306 shares — an estimated $184K sold.

MBB Public Markets first reported a position in ALLO in Q1 2023 and held it in 4 quarters. The position peaked at $426K in Q2 2023. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

  • MBB Public Markets reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
  • MBB Public Markets sold 57,306 Allogene Therapeutics shares in Q1 2024, an estimated $184K.
  • MBB Public Markets first reported a position in Allogene Therapeutics in Q1 2023 and held it in 4 quarters.
  • MBB Public Markets's Allogene Therapeutics position peaked at $426K in Q2 2023.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on MBB Public Markets's 13F filing for Q1 2024, filed 15 May 2024.